nilotinib (Tasigna)
Jump to navigation
Jump to search
Indications
- FDA-approved for Philadelphia chromosome-positive CML
- may have disease-modifying benefits in Alzheimer's disease[4]
- Parkinson's disease?[5][6]; Lewy body disease?[6]
Dosage
Capsules 150 mg
Pharmacokinetics
- crosses blood-brain barrier
- metabolized by CYP3A4
Monitor
- liver function tests periodically
Adverse effects
Drug interactions
Mechanism of action
- tyrosine kinase inhibitor
- targets discoidin domain receptors, including Abelson tyrosine kinase
- increases CSF dopamine turnover
- reduces CSF tau (indcependent of Abelson tyrosine kinase inhibition))
More general terms
References
- ↑ Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260704&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 2.0 2.1 Nelson R FDA Updates Labeling for Nilotinib: Treatment Can Be Stopped. Medscape - Dec 22, 2017. https://www.medscape.com/viewarticle/890566
- ↑ Ingram I. FDA OKs Tasigna for Rare Leukemia in Children. Approved in first- and second-line settings. MedPage Today. March 22, 2018 https://www.medpagetoday.com/hematologyoncology/leukemia/71936
- ↑ 4.0 4.1 George J Alzheimer's Markers Altered With Cancer Drug -Early nilotinib study suggests it has potential to be a disease-modifying drug. MedPage Today May 29, 2020 https://www.medpagetoday.com/neurology/alzheimersdisease/86770
Nackerdien Z Cancer Drug Nilotinib Changes Alzheimer's Disease Biomarkers - his may be a first step towards a disease-modifying treatment, phase II study suggests. MedPage Today 2020-06-18 https://www.medpagetoday.org/neurology/alzheimersdisease/87151
Turner RS, Hebron ML, Lawler A et al Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease. Ann Neurol 2020. May 28 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32468646 https://onlinelibrary.wiley.com/doi/full/10.1002/ana.25775 - ↑ 5.0 5.1 Pagan FL, Hebron ML, Wilmarth B et al Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2019 Dec 16;77(3):309-17 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31841599 Free PMC article
- ↑ 6.0 6.1 6.2 Pagan F, Hebron M, Valadez EH et al Nilotinib Effects in Parkinson's disease and Dementia with Lewy bodies. J Parkinsons Dis. 2016 Jul 11;6(3):503-17. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27434297 Free PMC article.